Works matching IS 17762596 AND DT 2025 AND VI 20 AND IP 1

Results: 15

Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial: Fruquintinib Plus Sintilimab in Patients with Advanced Renal Cell Carcinoma: H. Xu et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 113, doi. 10.1007/s11523-024-01120-6

By:

Xu, Hua;
Yao, Xin;
He, Zhisong;
Luo, Hong;
Li, Guiling;
Guo, Jianming;
Diao, Lei;
Fan, Yu;
Li, Yuan;
Fan, Jiquan;
Hu, Xiaoyi;
Lu, Puhan;
Shi, Haiyan;
Chen, Keyan;
Tan, Panfeng;
Fan, Songhua;
Shi, Michael;
Su, Weiguo;
Ye, Dingwei

Publication type:

Article

FGFR-Altered Urothelial Carcinoma: Resistance Mechanisms and Therapeutic Strategies: FGFR-Altered Urothelial Carcinoma: D. J. Benjamin, A. C. Mita.

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 1, doi. 10.1007/s11523-024-01119-z

By:

Benjamin, David J.;
Mita, Alain C.

Publication type:

Article

Immunotherapy Following Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients with Anaplastic Lymphoma Kinase‑Positive Non‑small Cell Lung Cancer in Japan: Immunotherapy Following ALK Inhibitors for Patients with ALK-Positive NSCLC in Japan: Y. Shimomura et al

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 171, doi. 10.1007/s11523-024-01116-2

By:

Shimomura, Yuki;
Mizutani, Megumi;
Yoshida, Hisako;
Ihara, Yasutaka;
Shintani, Ayumi

Publication type:

Article

Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy: PACIFIC Regimen: Survival Based on Age and Subsequent Therapy: D. Ksienski et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 149, doi. 10.1007/s11523-024-01111-7

By:

Ksienski, Doran;
Truong, Pauline T.;
Bone, Jeffrey N.;
Egli, Sarah;
Clarkson, Melissa;
Patterson, Tiffany;
Lesperance, Mary;
Lakkunarajah, Suganija

Publication type:

Article

Correction: Ivosidenib: A Review in Advanced Cholangiocarcinoma: Correction: Ivosidenib: A Review in Advanced Cholangiocarcinoma: J. E. Frampton et al.

Published in:

2025

By:

Frampton, James E.

Publication type:

Correction Notice

Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies: CDK4/6 Inhibitors for Patients with Breast Cancer: H.-C. Su et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 71, doi. 10.1007/s11523-024-01118-0

By:

Su, Hui-Chen;
Lin, Ho-Wei;
Tam, Ka-Wai

Publication type:

Article

Defining the Position of [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis of Clinical Trials: [<sup>177</sup>Lu]Lu-PSMA RLT in mCRPC: A Meta-analysis of Clinical Trials: C. Ciccarese et al

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 103, doi. 10.1007/s11523-024-01117-1

By:

Ciccarese, Chiara;
Bauckneht, Matteo;
Zagaria, Luca;
Fornarini, Giuseppe;
Beccia, Viria;
Lanfranchi, Francesco;
Perotti, Germano;
Pinterpe, Giada;
Migliaccio, Fortuna;
Tortora, Giampaolo;
Leccisotti, Lucia;
Sambuceti, Gianmario;
Giordano, Alessandro;
Caffo, Orazio;
Iacovelli, Roberto

Publication type:

Article

Unveiling the Digital Evolution of Molecular Tumor Boards: Unveiling the Digital Evolution of Molecular Tumor Boards: S. Lutz et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 27, doi. 10.1007/s11523-024-01109-1

By:

Lutz, Sebastian;
D'Angelo, Alicia;
Hammerl, Sonja;
Schmutz, Maximilian;
Claus, Rainer;
Fischer, Nina M.;
Kramer, Frank;
Hammoud, Zaynab

Publication type:

Article

IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma: IDH1/2 Mutations in Chondrosarcoma: S. Deshmukh et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 13, doi. 10.1007/s11523-024-01115-3

By:

Deshmukh, Shriya;
Kelly, Ciara;
Tinoco, Gabriel

Publication type:

Article

Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis: Adjuvant Immunotherapy for Urothelial Carcinoma: T. Yanagisawa et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 57, doi. 10.1007/s11523-024-01114-4

By:

Yanagisawa, Takafumi;
Mori, Keiichiro;
Matsukawa, Akihiro;
Kawada, Tatsushi;
Katayama, Satoshi;
Laukhtina, Ekaterina;
Rajwa, Pawel;
Quhal, Fahad;
Pradere, Benjamin;
Fukuokaya, Wataru;
Iwatani, Kosuke;
Afferi, Luca;
Marcq, Gautier;
Mertens, Laura S.;
Gallioli, Andrea;
Tully, Karl H.;
Caño-Velasco, Jorge;
Subiela, José Daniel;
Abu-Ghanem, Yasmin;
Grobet-Jeandin, Elisabeth

Publication type:

Article

Post-Metastasis Survival of Patients with High-Risk Localized and Locally Advanced Prostate Cancer Undergoing Primary Treatment in the United States: A Retrospective Study: Post-Metastasis Survival of Patients with High-Risk Localized and Locally Advanced Prostate Cancer: Stephen J. Freedland et al

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 139, doi. 10.1007/s11523-024-01113-5

By:

Freedland, Stephen J.;
Fernandes, Luis;
De Solda, Francesco;
Buyukkaramikli, Nasuh;
Mundle, Suneel D.;
McCarthy, Sharon A.;
Labson, Daniel;
Yang, Lingfeng;
Pan, Feng;
Mir, Carmen

Publication type:

Article

Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors: Adavosertib Plus Durvalumab for Solid Tumors: A Phase I Study: M.R. Patel et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 127, doi. 10.1007/s11523-024-01110-8

By:

Patel, Manish R.;
Falchook, Gerald S.;
Wang, Judy S.;
Imedio, Esteban Rodrigo;
Kumar, Sanjeev;
Miah, Kowser;
Mugundu, Ganesh M.;
Jones, Suzanne F.;
Spigel, David R.;
Hamilton, Erika P.

Publication type:

Article

Delayed Separation of Kaplan–Meier Curves is Commonly Observed in Studies of Advanced/Metastatic Solid Tumors Treated with Anti-PD-(L)1 Therapy: Systematic Review and Meta-Analysis: Delayed Separation of KM Curves with Anti-PD-(L)1 Therapy: D.-Y. Oh et al

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 45, doi. 10.1007/s11523-024-01108-2

By:

Oh, Do-Youn;
Rokutanda, Nana;
Żotkiewicz, Magdalena;
He, Philip;
Stocks, Jennifer;
Johnson, Melissa L.

Publication type:

Article

Risk and Benefit for Basket Trials in Oncology: A Systematic Review and Meta-Analysis: Risk and Benefit for Basket Trials in Oncology: K. Klas et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 89, doi. 10.1007/s11523-024-01107-3

By:

Klas, Katarzyna;
Strzebonska, Karolina;
Zaborowska, Lucja;
Krawczyk, Tomasz;
Włodarczyk, Alicja;
Bąk-Kuchejda, Urszula;
Polak, Maciej;
Van Wambeke, Simon;
Waligora, Marcin

Publication type:

Article

Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study: Duration of Durvalumab Following CCRT in Stage III NSCLC: H. Doi et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 161, doi. 10.1007/s11523-024-01105-5

By:

Doi, Hiroshi;
Matsuo, Yukinori;
Kishi, Noriko;
Ogura, Masakazu;
Mitsuyoshi, Takamasa;
Ueki, Nami;
Ueki, Kazuhito;
Fujii, Kota;
Sakamoto, Masato;
Atsuta, Tomoko;
Katagiri, Tomohiro;
Sakamoto, Takashi;
Narabayashi, Masaru;
Ohtsu, Shuji;
Fujishiro, Satsuki;
Kishi, Takahiro;
Mizowaki, Takashi

Publication type:

Article